Establishing combination PAC-1 and TRAIL regimens for treating ovarian cancer based on patient-specific pharmacokinetic profiles using in silico clinical trials
O. Cardinal, C. Burlot, Y. Fu, P. Crosley, M. Hitt, M. Craig, A. L. Jenner
This paper uses in silico clinical trials to optimize combination PAC-1 and TRAIL therapy for ovarian cancer based on patient-specific pharmacokinetic profiles, identifying optimal treatment schedules and patient subgroups.
bioRxiv · Mar 29, 2022Cancer Biology